Tyra Biosciences Shares Plunge After SURF302 Phase 2 Data Release
Tyra Biosciences saw its stock drop about 30% on Wednesday after publishing initial Phase 2 SURF302 trial outcomes for dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer. The data showed a 79% overall response rate and a 64% complete response rate for the combined single and multiple marker le…